Barclays
VIRX

Barclays’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Barclays’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,338
Closed -$6.38M – 7662
2014
Q3 		$6.38M Buy
+4,338
New +$6.28M 0.01% 1556

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Barclays's VIRX Position: Q3 2024 in Review

Barclays sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2024, closing a stake of 2,668 shares — an estimated $1.45K sold.

Barclays first reported a position in VIRX in Q2 2013 and held it in 18 quarters. The position peaked at $577K in Q3 2014. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

  • Barclays reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Barclays sold 2,668 Viracta Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.45K.
  • Barclays first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • Barclays's Viracta Therapeutics, Inc. Common Stock position peaked at $577K in Q3 2014.
  • 38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.